ORMP ORAMED PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ORAMED PHARMACEUTICALS INC reported revenue of n/a, net income of $78.2M and diluted EPS of $1.84; for the fiscal year ended December 2025 revenue was $2.00M.
ORMP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $2.00M, gross profit $13.0K, operating income −$15.1M, net income $75.3K (margin 3.8%), EPS $1.50
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$12.8M, net income −$15.9K (margin n/a), EPS −$0.48
- Fiscal year ended Dec 2023: revenue $1.34M, gross profit n/a, operating income −$15.8M, net income $5.09K (margin 0.4%), EPS $0.14
- Fiscal year ended Dec 2022: revenue $2.70M, gross profit n/a, operating income −$40.6M, net income −$36.6M (margin -1352.6%), EPS −$0.94
- Fiscal year ended Aug 2021: revenue $2.70M, gross profit n/a, operating income −$24.2M, net income −$23.0M (margin -850.5%), EPS $0.78
ORMP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $78.2M, EPS $1.84
- Quarter ended Mar 31, 2026: revenue n/a, net income $38.3M, EPS $0.91
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$54.0M, EPS $0.25
- Quarter ended Sep 30, 2025: revenue n/a, net income $48.4M, EPS $1.13
- Quarter ended Jun 30, 2025: revenue n/a, net income $13.3M, EPS $0.31
- Quarter ended Mar 31, 2025: revenue $2.00M, net income −$7.64M, EPS −$0.19
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $8.86M, EPS −$0.26
- Quarter ended Sep 30, 2024: revenue n/a, net income −$19.6M, EPS −$0.48
- Quarter ended Jun 30, 2024: revenue n/a, net income $9.21M, EPS $0.22
- Quarter ended Mar 31, 2024: revenue n/a, net income $1.54M, EPS $0.04
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $7.82M, EPS $0.33
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.22M, EPS −$0.08
- Quarter ended Jun 30, 2023: revenue $674K (up 0.0% year over year), net income −$1.19M, EPS −$0.03
- Quarter ended Mar 31, 2023: revenue $666K (up 0.0% year over year), net income −$3.40M, EPS −$0.08
- Quarter ended Dec 31, 2022: revenue $904K (up 0.0% year over year), net income −$12.3M, EPS $0.31
- Quarter ended Sep 30, 2022: revenue $682K (up 0.0% year over year), net income −$7.06M, EPS $0.18
- Quarter ended Jun 30, 2022: revenue $674K (up 0.0% year over year), net income −$10.5M, EPS $0.27
- Quarter ended Mar 31, 2022: revenue $666K (up 0.0% year over year), net income −$10.7M, EPS $0.27
- Quarter ended Dec 31, 2021: revenue $904K, net income −$12.3M, EPS $0.31
- Quarter ended Sep 30, 2021: revenue $682K, net income −$7.54M, EPS $0.21
ORMP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$9.15M, share buybacks $4.74M
- Fiscal year ended Dec 2024: operating cash flow −$8.41M, share buybacks $2.48M
- Fiscal year ended Dec 2023: operating cash flow −$10.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$27.9M, share buybacks n/a
- Fiscal year ended Aug 2021: operating cash flow −$21.2M, share buybacks n/a
ORMP balance sheet
- Jun 30, 2026: cash $15.2M, total assets $370M, total liabilities n/a, shareholders' equity n/a
- Mar 31, 2026: cash $13.2M, total assets $269M, total liabilities n/a, shareholders' equity n/a
- Dec 31, 2025: cash $45.9M, total assets $231M, total liabilities n/a, shareholders' equity $200M
- Sep 30, 2025: cash $52.2M, total assets $220M, total liabilities n/a, shareholders' equity $203M
- Jun 30, 2025: cash $15.8M, total assets $162M, total liabilities n/a, shareholders' equity $155M
- Mar 31, 2025: cash n/a, total assets $148M, total liabilities n/a, shareholders' equity $141M
- Dec 31, 2024: cash $54.4M, total assets $155M, total liabilities n/a, shareholders' equity $146M
- Sep 30, 2024: cash n/a, total assets $165M, total liabilities n/a, shareholders' equity $156M
What is ORMP's revenue?
ORAMED PHARMACEUTICALS INC reported $2.00M of revenue for the fiscal year ended December 2025.
Is ORMP profitable?
Yes. ORAMED PHARMACEUTICALS INC earned $111M over the last four quarters.
What is ORMP's EPS?
Diluted earnings per share over the last four quarters were $4.13; $1.84 in the latest quarter.